Failed in phase 2
Estriol: reduce relapses and new lesions in relapsing MS
relapsing MS · Sex hormones / hormonal
Controlled phase 2 trials did not meet their main goal for this group.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 158
How the verdict was reached
Negative in phase 2
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Estriol-MS | Phase 2 | 158 | 2007 | Missed its main goal | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Failed in phase 2
Related hypotheses
- Testosterone undecanoate: protect nerve tissue in relapsing MS
- Testosterone: protect nerve tissue in relapsing MS
- Sex hormones / hormonal: repair myelin in relapsing MS
- Somatropin: reduce relapses and new lesions in relapsing MS
- Testosterone undecanoate: reduce relapses and new lesions in relapsing MS
- Testosterone: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources.